Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1096-e1105. doi: 10.1210/clinem/dgab781.
Little is known about provider specialties involved in thyroid cancer diagnosis and management.
Characterize providers involved in diagnosing and treating thyroid cancer.
DESIGN/SETTING/PARTICIPANTS: We surveyed patients with differentiated thyroid cancer from the Georgia and Los Angeles County Surveillance, Epidemiology and End Results registries (N = 2632, 63% response rate). Patients identified their primary care physicians (PCPs), who were also surveyed (N = 162, 56% response rate).
(1) Patient-reported provider involvement (endocrinologist, surgeon, PCP) at diagnosis and treatment; (2) PCP-reported involvement (more vs less) and comfort (more vs less) with discussing diagnosis and treatment.
Among thyroid cancer patients, 40.6% reported being informed of their diagnosis by their surgeon, 37.9% by their endocrinologist, and 13.5% by their PCP. Patients reported discussing their treatment with their surgeon (71.7%), endocrinologist (69.6%), and PCP (33.3%). Physician specialty involvement in diagnosis and treatment varied by patient race/ethnicity and age. For example, Hispanic patients (vs non-Hispanic White) were more likely to report their PCP informed them of their diagnosis (odds ratio [OR]: 1.68; 95% CI, 1.24-2.27). Patients ≥65 years (vs <45 years) were more likely to discuss treatment with their PCP (OR: 1.59; 95% CI, 1.22-2.08). Although 74% of PCPs reported discussing their patients' diagnosis and 62% their treatment, only 66% and 48%, respectively, were comfortable doing so.
PCPs were involved in thyroid cancer diagnosis and treatment, and their involvement was greater among older patients and patients of minority race/ethnicity. This suggests an opportunity to leverage PCP involvement in thyroid cancer management to improve health and quality of care outcomes for vulnerable patients.
对于参与甲状腺癌诊断和治疗的医生专业领域所知甚少。
描述参与甲状腺癌诊断和治疗的医生。
设计/设置/参与者:我们调查了来自佐治亚州和洛杉矶县监测、流行病学和结果注册中心的分化型甲状腺癌患者(N=2632,应答率为 63%)。我们还对患者的初级保健医生(PCP)进行了调查(N=162,应答率为 56%)。
(1)患者报告的诊断和治疗时的医生参与情况(内分泌科医生、外科医生、PCP);(2)PCP 报告的参与程度(更多与更少)和讨论诊断与治疗的舒适度(更多与更少)。
在甲状腺癌患者中,40.6%的患者报告其外科医生告知其诊断结果,37.9%的患者报告其内分泌科医生告知其诊断结果,13.5%的患者报告其 PCP 告知其诊断结果。患者报告与外科医生(71.7%)、内分泌科医生(69.6%)和 PCP(33.3%)讨论了治疗方案。诊断和治疗中的医生专业领域的参与因患者的种族/民族和年龄而异。例如,与非西班牙裔白人相比,西班牙裔患者更有可能报告其 PCP 告知其诊断结果(优势比[OR]:1.68;95%置信区间,1.24-2.27)。年龄≥65 岁的患者(vs 年龄<45 岁)更有可能与 PCP 讨论治疗方案(OR:1.59;95%置信区间,1.22-2.08)。尽管 74%的 PCP 报告与患者讨论了诊断结果,62%的 PCP 报告与患者讨论了治疗方案,但分别只有 66%和 48%的 PCP 表示他们对此感到舒适。
PCP 参与了甲状腺癌的诊断和治疗,在年龄较大和少数族裔/少数民族患者中,PCP 的参与度更高。这表明可以利用 PCP 对甲状腺癌管理的参与,改善弱势患者的健康和护理质量结果。